Outcomes of Unintentional beta-Blocker or Calcium Channel Blocker Overdoses: a Retrospective Review of Poison Center Data

被引:0
|
作者
Carrie A. Truitt
Daniel E. Brooks
Paul Dommer
Frank LoVecchio
机构
[1] Banner Good Samaritan Poison and Drug Information Center,Department of Emergency Medicine
[2] Maricopa Medical Center,Department of Medical Toxicology
[3] Banner Good Samaritan Medical Center,undefined
关键词
-Blocker toxicity; Calcium channel blocker toxicity; Poison center utilization; Management of unintentional ingestions;
D O I
10.1007/s13181-011-0209-8
中图分类号
学科分类号
摘要
Outcomes following unintentional, supratherapeutic ingestions of a patient’s own beta-blocker (BB) or calcium channel blocker (CCB) have not been well studied. A retrospective review of all poison control center (PCC) charts from January 2007 through December 2009 yielded 4,099 cases involving a BB or CCB. Of these, 436 (10.6%) met inclusion criteria. Data abstracted included patient age/gender, medication(s) involved, dose(s), time interval between ingestions, symptoms, and outcome. Exclusion criteria included intentional ingestions, ingesting someone else’s medication, and ingestion intervals >12 h. Outcomes were defined as the development of symptoms, management site, hospital admission, and death. Mean age was 65.1 years (range 2–91; SD 17.9); 284 (65.1%) were women. Eighty-two (18.8%) cases resulted in ED evaluation; 44 (53.7%) of these were referred in by the PCC. Symptoms developed in 44 (10.1%) cases and 32 (7.3%) were admitted due to the ingestion. Of those admitted, five (15.6%) received treatment (three intravenous fluids, one glucagon, one calcium). Of the 343 (78.7%) cases initially observed on site, three (0.9%) were later referred to an ED; none required treatment. There was one death under extenuating circumstances. The validity of data abstraction was determined for six variable using 43 charts [0.97; 95% CI (0.91–0.99)]. Based on a retrospective analysis of PCC cases, home observation of asymptomatic patients following unintentional supratherapeutic ingestions of their own BB or CCB was safe in most cases. Further, prospective study is required to identify risks factors for becoming symptomatic or requiring treatment.
引用
收藏
页码:135 / 139
页数:4
相关论文
共 50 条
  • [31] The beneficial effects of beta-blocker and calcium-channel blocker on atrial fibrillation in patients with chronic heart failure
    Tamaki, S
    Yamada, T
    Mine, T
    Morita, T
    Kioka, H
    Tsukamoto, Y
    Masuda, M
    Okuda, K
    Fukunami, M
    JOURNAL OF CARDIAC FAILURE, 2005, 11 (09) : S295 - S295
  • [32] Calcium channel blocker poisonings in Denmark: 5 years' data from the Danish Poison Information Center
    Al-Gibouri, Salam
    Andersen, Jon T.
    Jimenez-Solem, Espen
    Petersen, Kasper M.
    Bogevig, Soren
    Petersen, Tonny S.
    Dalhoff, Kim
    Christensen, Mikkel
    CLINICAL TOXICOLOGY, 2016, 54 (04) : 425 - 425
  • [33] Peripartum cardiomyopathy outcomes in the beta-blocker era
    Hata, AM
    Jaber, WA
    Russell, SD
    JOURNAL OF CARDIAC FAILURE, 2004, 10 (04) : S96 - S96
  • [34] High-dose insulin infusion in calcium channel and beta-blocker overdose
    Sherwin, S.
    MacDonald, J.
    ANAESTHESIA, 2019, 74 : 64 - 64
  • [35] A Comparison of High Dose Insulin Therapy and Conventional Inotropic Therapy in Calcium Channel Blocker And/or Beta-Blocker Toxic Ingestions
    Musselman, M.
    Farber, M.
    Smolinske, S.
    Aaron, C.
    Saely, S.
    ANNALS OF EMERGENCY MEDICINE, 2011, 58 (04) : S325 - S325
  • [36] A COMPARISON OF THE EFFICACY AND SAFETY OF A BETA-BLOCKER, A CALCIUM-CHANNEL BLOCKER, AND A CONVERTING-ENZYME-INHIBITOR IN HYPERTENSIVE BLACKS
    SAUNDERS, E
    WEIR, MR
    KONG, BW
    HOLLIFIELD, J
    GRAY, J
    VERTES, V
    SOWERS, JR
    ZEMEL, MB
    CURRY, C
    SCHOENBERGER, J
    WRIGHT, JT
    KIRKENDALL, W
    CONRADI, EC
    JENKINS, P
    MCLEAN, B
    MASSIE, B
    BERENSON, G
    FLAMENBAUM, W
    ARCHIVES OF INTERNAL MEDICINE, 1990, 150 (08) : 1707 - 1713
  • [37] Treatment for beta-blocker poisoning: a systematic review
    Rotella, Joe-Anthony
    Greene, Shaun L.
    Koutsogiannis, Zeff
    Graudins, Andis
    Hung Leang, Yit
    Kuan, Kelvin
    Baxter, Helen
    Bourke, Elyssia
    Wong, Anselm
    CLINICAL TOXICOLOGY, 2020, 58 (10) : 943 - 983
  • [38] BASIC REVIEW AND COMPARISON OF BETA-BLOCKER PHARMACOKINETICS
    SUNDQUIST, H
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1980, 28 (01): : S38 - S44
  • [39] SUICIDAL AND ACCIDENTAL POISONINGS FROM OVERDOSES OF A HIGHLY EFFECTIVE BETA-BLOCKER (TALINOLOL)
    OLTMANNS, G
    SCHWELA, H
    MICHAELIS, K
    DEMME, U
    HAHN, W
    KOHLER, P
    KULICK, B
    SCHMIDT, H
    KEMPA, S
    MEIXNER, R
    DITTRICH, P
    KNAPPE, J
    DEUTSCHE GESUNDHEITSWESEN-ZEITSCHRIFT FUR KLINISCHE MEDIZIN, 1982, 37 (06): : 277 - 283
  • [40] Lack of clinically meaningful changes in cardiac effects from co-administration of ozanimod and a beta-blocker or a calcium channel blocker
    Boyd, J. L.
    Walker, S.
    Mccloskey, P.
    Syto, M.
    Darpo, B.
    Tran, J. Q.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 913 - 914